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3Abstract 
Melanoma is a devastating form of skin cancer with high tendency to metastasis. This work 
addresses the development of new targeted nanoparticles that can be used for SPECT imaging of 
melanoma. Melanoma-specific glycoprotein non-metastatic b (GPNMB) antigen targeted and non-
targeted gemini nanoparticles were prepared, characterized and radiolabeled with 111In. 111In-
labeled nanoparticles comprised of gemini surfactant grafted with monoclonal antibody Fab 
fragment that targets GPNMB. Specific uptake of GPNMB-Fab was studied in six melanoma cell 
lines using flow cytometry. In vitro cellular uptake and internalization was studied using flow 
cytometry, confocal laser scanning microscopy and radiometric techniques. Specific uptake of 
anti-GPNMB targeted nanoparticles was observed in GPNMB expressing cells which was higher 
than low expressing or control cells. In vitro studies showed that conjugation of GPNMB targeted 
nanoparticles led to enhanced intracellular uptake of the nanodelivery system which is critical for 
drug delivery. In vivo distribution of the nanoparticles was studied by microSPECT/CT imaging 
and ex vivo biodistribution. Tumor uptake was significantly higher (p <0.05) in non-targeted 
nanoparticles (5.47 ± 0.46 %IA/cc) compared to GPNMB targeted nanoparticles (1.87 ± 0.27 % 
ID/cc), which might be attributed to the high spleen uptake of the targeted formulation. These 
findings demonstrated that the radiolabeled gemini nanoparticles are promising for image-guided 
radiotherapy of melanoma. Formulation optimization is needed to improved tumor uptake and in 
vivo intracellular delivery for radiotherapeutic applications. 
Key words: GPNMB Nanoparticles; Theranostics; 111Indium; Gemini; Melanoma; Imaging
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4Introduction
Melanoma is the deadliest form of skin cancer due to its high propensity of metastasis and 
limited treatment options. The rise in the incidence of melanoma in the last 50 years is the highest 
among all cancers 1. The five-year survival rates for melanoma that has metastasize to lymph nodes 
or other organs is 17% 2. Early diagnosis and surgery are the patients’ best hope for managing 
early stages of melanoma. The median progression-free survival for the FDA-approved 
pembrolizumab , while better than other therapies, is 5.5 months which is lower than the same 
treatment in lung cancer (6.3 months) 3. Two approaches could reduce melanoma morbidity and 
mortality: early detection and the development of novel therapies to expand the current arsenal. 
Novel nanoparticle formulations could address both areas: development of sensitive diagnostic 
tools and targeted delivery of curative agents. Enhanced permeability and retention effect (EPR) 
allows extravasation of the nanoparticles into the tumour through the leaky vasculature, leading to 
their preferential accumulation compared to healthy tissue4. In addition, nanoparticles might 
bypass certain uptake barriers such as epithelial tight junction 5. Nanoparticles can be 
functionalized with targeting peptides and radionuclides for use as diagnostics and targeted 
radiotherapeutics 6. Imaging and therapeutic radionuclides can be effectively delivered to tumor 
site by functionalized nanoparticles, thus improving imaging quality and therapeutic efficiency 7. 
Our research group focuses on the design and synthesis of gemini surfactants to build drug delivery 
nanoparticles 8,9. Gemini surfactants, N,N-bis(dimethylalkyl)-α,ω-alkanediammonium halide 
derivatives, have been shown to be attractive in the drug delivery field10. They are simply two 
surfactants chemically connected by a spacer. The physicochemical properties of these compounds 
can be modulated by the modification in the structure of the alkyl tails and the spacer groups. 
Alteration of the alkyl chain length, substitution of different functional groups and the degree of 
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5unsaturation provide the possibility to tailor specific compounds for a certain need 9. Gemini 
surfactants self-assemble into nanoparticles, which adopt various morphologies (micelles, inverted 
micelles, liposomes, cubosomes) to deliver small and large molecules and radionuclides to tumor 
cells 10.
Monoclonal antibody against glycoprotein NMB (GPNMB) was selected as a targeting vector. 
GPNMB is a 560-amino acid glycosylated transmembrane protein structurally similar to pMEL-
17, a melanocyte specific marker that is specifically expressed in melanoma cells 11. Compared to 
healthy cells, tumours such as breast cancer, melanoma and glioblastoma overexpress GPNMB, 
presenting a new class of targets for these types of cancer 12,13. Overexpression of GPNMB 
promotes metastasis, reduces cells apoptosis and increases angiogenesis in tumors 14. 
Glembatumumab vedotin, an antibody drug conjugate of anti-GPNMB antibody and antimitotic 
agent monomethyl auristatin E, is in clinical trials for melanoma and breast cancer 15,16,17. 
However, the results have not been promising. A subgroup analysis (involving a small number of 
patients) of a phase II trial in triple negative breast cancer (TNBC) patients whose tumors 
overexpress GPNMB showed an advantage of glembatumumab vedotin over capecitabine 
(Xeloda®) 16,17. However, a recent pivotal phase IIb study in a large cohort of TNBC patients 
whose tumors overexpress > 25% of GPNMB, failed to show an advantage of glembatumumab 
vedotin over capecitatbine 18. Unlike antibodies/ADCs against other antigens such as epidermal 
growth factor receptor II (HER 2) where the interaction of the antigen with other receptors has 
been shown to be responsible for poor response in some patients, the interaction of GPNMB with 
other receptors has not been well studied. Another factor responsible for poor efficacy of antibody 
drug conjugates is the presence of drug efflux pump multidrug resistance gene 19. 
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6111In was selected as the imaging radionuclide as its physical decay (t1/2 2.8 days) is ideally 
suited for single-photon emission computed tomography (SPECT) imaging of long circulating 
nanodelivery systems. SPECT imaging has high sensitivity and good spatial resolution, and it is 
becoming an indispensable technique for in vivo imaging 20. In this study we have used 111In to 
evaluate the in vivo properties of the nanodelivery system. The rationale for the choice of DOTA 
as chelating agent is that it can be used for imaging (with 111In) and subsequently for alpha particle 
therapy (actinium-225: 225Ac) for alpha particle radiotherapy. This allows us to use 111In as a 
surrogate to understand the in vitro and in vivo characteristics of the nanodelivery system. Alpha 
particle therapy causes irreversible DNA double-strand break due to its high linear energy transfer 
(LET), approximately 25-230 kEv/μm, which is about 100 to 1000 times the average LET of beta 
particles 21.  The overall goal of the study was to develop and evaluate an 111In-labeled germini 
sulfactant nanodelivery system containing anti-GPNMB fab fragment in cells and mouse models 
of GPNMB overexpressing melanoma. 
Materials and methods
Materials
Anti-GPNMB therapeutic antibody (glembatumumab) Fab (GPNMB-Fab) was purchased 
from Creative Biolabs NY, USA). Helper lipid 1, 2 dioleyl-sn-glycero-phosphatidylethanolamine 
(DOPE), 1,2 Dipalmitoyl-sn-glycero-phosphocholine (DPPC) and 1,2 Distearoyl-sn-glycero-
phosphocholine (DSPC)  were purchased from Avanti Polar Lipids (Alabaster, AL). 
111In was purchased from Nordion Inc. (Ottawa, ON). Activity measurements were made 
using a Biodex Atomlab 500 Dose Calibrator (Shirley, NY). For accurate quantification of 
activities, samples were counted for 1 min on a calibrated Perkin-Elmer Automatic Wizard2 
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7Gamma Counter (Waltham, MA). Labeling of nanoparticles with 111In was monitored using silica-
gel impregnated glass-fiber instant thin layer chromatography (iTLC) paper (Agilent 
Technologies, Santa Clara, CA).
Formulation of gemini surfactant nanoparticles
Lipid film hydration method was adopted to prepare gemini nanoparticles using DOPE, DPPC 
or DSPC as helper lipids. A homogenous lipid film was obtained by dissolving gemini surfactant, 
DOPE and DSPC or DPPC in anhydrous ethanol with the aid of sonication at room temperature 
for 10 minutes. Ethanol was then removed by evaporation under reduced pressure at 50 °C using 
rotavap (BÜCHI Heating Bath B-490, vacuum pump V-700, Flawil). The lipid film was stored in 
-80 °C for 12 hand freeze dried using Labconco® Freezone Plus 6 L cascade freeze dryer, MO, 
USA at -80 ˚C and 0.03 mBar pressure for 24 h to remove ethanol residues. Nanoparticles are 
formed by hydration of the lipid film using isotonic sucrose solution (9.25 %) in phosphate 
buffered saline of pH 7.4 (PBS) (HyCloneTM, Hyclone Laboratories. Logan UT).   Lipid film 
hydration was performed by ultrasonication (Elma ultrasonic, Singen) at 50 °C for two hours. The 
obtained nanoparticle suspension was filtered through Acrodisc® 0.45 µm syringe filter (Pall 
Gelman, Ann Arbor, MI). Table 1 summarizes the composition of the prepared gemini 
nanoparticles. In all analyses, triplicate batches of each formulation were evaluated.
Characterization of gemini surfactant nanoparticles
The size and zeta-potential of the particles were measured using Zetasizer Nano ZS instrument 
(Malvern Instrument, UK). Results are reported as the mean of 3 – 5 measurements ± standard 
deviation. Aliquots of 10 µL samples were dropped onto 300-mesh formvar-coated copper grids 
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8(SPI Supplies). The water was blotted with absorbent tissue and samples were examined using 
Philips CM10 electron microscope (Eindhoven, The Netherlands).  
Preparation of fluorescent labeled gemini surfactant nanoparticles
The lipophilic marker (DiO; ex/em wavelength 484nm/501nm) was integrated in the lipid film 
at a final concentration of 0.2 mg/mL of nanoparticle dispersion, while the hydrophilic tracer 
(FITC-Dextran; ex/em wavelength 492nm/518nm) was dissolved in the hydration solution at 
concentration of 1 mg/mL. Nanoparticles were prepared applying the same procedures as 
mentioned before.
Flow cytometry analysis
After initial passage in tissue culture flasks, RPMI-7951 and A375cells were grown in 6-well 
plates. When reached 70-80% confluence, the cells were washed with PBS and treated with FBS 
free medium containing 10% fluorescent gemini nanoparticle dispersion or dye solution in PBS 
(0.2 mg/mL for Dio and 1 mg/mL for FITC-dextran). After two hours incubation at 37 °C, cells 
were washed with PBS, collected by trypsinisation, pelleted, washed with 4 mL PBS and 
resuspended in 500 µL PBS for flow cytometry.
Flow cytometric analysis (FACS analysis) for nanoparticles’ fluorescence was performed 
using a 4-color FACS-Calibur (Becton Dickinson, Heidelberg, Germany) equipped with an argon 
laser exciting at a wavelength of 488 nm. For each sample, 10000 events were collected by list-
mode data that consisted of side scatter, forward scatter and fluorescence emission centered at 530 
nm (FL1) for DiO and FITC-dextran. For Alexa Flour® 647detection, a long-pass filter with a 
cutoff of 670 nm (FL3) was applied. Cell Quest Pro software (Becton Dickinson, Heidelberg, 
Germany) was applied for the analyses.
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9Confocal laser scanning microscopy
For confocal microscopy, the cells were grown on cover slips in 6-well-plates, and the same 
procedures for cellular uptake experiment were followed but after incubation and washing, the 
cells were treated with FBS free medium and imaged using Leica TCS SP5 laser scanning confocal 
microscope (Leica microsysytems Inc., Benshein, Germany). LAS Af Lite 2.4.1 (Leica 
microsystems CMS GmbH) and FijiJ 1.44 (National Institute of Health, Bethesda MD) were used 
for image processing.
Synthesis of lysine-, DOTA-, and GPNMB-Fab-conjugated gemini surfactants
The synthesis of lysine-, DOTA-, and Fab-conjugated gemini surfactants are illustrated in 
Scheme 1. All reactions were carried out under a nitrogen atmosphere using standard Schlenk 
techniques. Mass spectra were obtained using a QSTAR XL MS/MS system. 1H NMR spectra 
were recorded using a Bruker 500 MHz Avance spectrometer. Chemical shifts, δ, are reported in 
parts per million, referenced to the residual 1H and 13C (DMSO-d6 at 2.50, 39.58), respectively. 
Purity of the compounds was further verified by reversed-phase (RP) HPLC (RP-HPLC) using an 
Agilent 1200 Series HPLC coupled to an UV detector and Waters 2796 HPLC System coupled to 
an UV and radiometric detector (Fig. S.1).
The synthesis of the N,N'-(((2-aminoacetyl)azanediyl)bis(propane-3,1-diyl))bis(N,N-
dimethylhexadecan-1-aminium) chloride (16-7NG-16) gemini surfactants used in this study have 
been previously described 22.
Synthesis of lysine-conjugated gemini surfactants
In step 1a, bis-boc-lysine, HATU, and DIPEA were sequentially placed in a 100-mL Schlenk 
flask containing 20 mL DMF at inert atmosphere to give a pale-yellow and later to a dark-red 
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10
mixture. After stirring for 15 min, 16-7NG-16 was added. DMF was removed under high vacuum 
after stirring for 18 h. To the residue, 100 mL DCM was added and then extracted with saturated 
sodium bicarbonate (5 × 100 mL). The extracted organic layer was dried over anhydrous sodium 
sulfate, and concentrated under vacuum to give the reddish oily compound. In the next step (step 
2b) the product was dissolved in 20 mL dry DCM followed by the addition of 10 mole equivalents 
of HCl (4 M in dioxane). After stirring for 2 h, excess solvent was removed and the residue was 
washed by decantation with diethyl ether. Finally, DCM was added to dissolve the compound and 
then it was precipitated using diethyl ether. This was repeated three times before the sample was 
dried under high vacuum. The final product 16-7NGK-16 had a yellowish to orange color.
16-7NGK-16: 1H NMR (500 MHz, DMSO-d6): δ = 8.93 (m) 1H, 8.44 (m) 3H, 8.27 (m) 3H, 4.15 
(d) 1H, 4.04 (d) 1H, 3.90 (m) 1H, 3.33 (m) 12H, 3.04(s) 6H, 3.04 (s) 6H, 2.72 (m) 4H, 2.01 (m) 
2H, 1.91 (m) 2H, 1.77 (m) 2H, 1.68–1.59 (m) 6H, 1.45 (m) 2H, 1.23 (m) 50H, 0.84 (t) 6H. MS-
TOF (m/z); calculated for C50H106N6O2 2+; expected 411.4183, found 411.4094.
Synthesis of DOTA-conjugated gemini surfactants 
In step 2, 0.014 mmol of 16-7NG-16 was dissolved in 2 mL DMSO. After stirring for 15 min, 
p-SCN-Bn-DOTA 0.014 mmol was added to the solution and the pH of the solution was adjusted 
to 8.5 by adding DIPEA. The mixture was stirred for 24 hours. The solvent was removed under 
vacuum and the product was separated by column chromatography (C18-reversed phase silica gel) 
eluting with water/acetonitrile. The appropriate fraction was freeze dried to obtain the N,N'-(((2-
(3-(4-((1,4,7,10-tetracarboxy-1,4,7,10-tetraazacyclododecan-2-
yl)methyl)phenyl)thioureido)acetyl)azanediyl)bis(propane-3,1-diyl))bis(N,N-
dimethylhexadecan-1-aminium) chloride, 16-7NG-DOTA-16, DOTA modified gemini surfactant 
solid product. The purity was further verified on RP-HPLC using Phenomenex Gemini-NX 
Page 10 of 45
ACS Paragon Plus Environment
Molecular Pharmaceutics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
11
(Phenomenex, United States) C18 analytical column (3µm, 4.6 mm X 150 mm). Gradient elution 
was performed at a flow rate of 1 mL/min using an Agilent 1200 Series HPLC system. Detection 
was performed using an Agilent absorbance detector at 254 nm. The mobile phase consisted of 
0.1% trifluoroacetic acid in H2O (solution A) and 0.1% trifluoroacetic acid in acetonitrile (solution 
B). The mobile phase was programmed as follows: gradient from 90 %A: 10 %B to 10 %A: 90 
%B in 30 min.
16-7NG-DOTA-16: 1H NMR (500 MHz, DMSO-d6): δ = 7.52 (m) 2H, 7.26 (m) 2H, 4.40 (m) 2H, 
3.43 m 25H, 3.24 (m) 9H, 2.99 (s) 6H, 3.03 (s) 6H, 2.55 (s) 3H, 2.04 (brs) 2H, 1.90 (brs) 2H, 1.65 
(brs) 4H, 1.24 (m) 50H, 0.86 (t) 6H. MS-TOF (m/z); calculated for C64H119N9O9S 2+; expected 
594.9420, found 594.9405.
Synthesis of GPNMB-Fab-conjugated gemini surfactants
In step 3, 0.144 mmol of 16-7NG-16 was dissolved in 10 mL DMSO. After stirring for 15 min, 
0.144 mmol of NHS-PEG1000-COOH was added to the solution and the pH of the solution was 
adjusted to 8.5 by adding DIPEA. The mixture was stirred for 24 hours and the solvent was 
removed under high vacuum. In the final step (step 4) EDC (0.033 µmol) and NHS (0.036 µmol) 
were added to a solution of (0.028 µmol) PEG1000-COOH conjugated gemini in 150 µL DMF and 
the reaction mixture was stirred at room temperature for 2 h. The crude product was directly added 
to the 1 mL GPNMB-Fab solution (465 µg/mL) in PBS and the mixture was stirred at 4°C for 30 
min. The resulting protein solution was purified by centrifugal filtration (molecular weight cut-
off, 10,000 Da) with PBS to obtain gemini-PEG1000-Fab (16-7NG-Fab-16).
Preparation of DOTA-gemini surfactant nanoparticles (DOTA-NP) and GPNMB-Fab-
DOTA-gemini surfactant nanoparticles (Fab-DOTA-NP)
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12
DOTA-gemini nanoparticles (DOTA-NP) were prepared by replacing 5 % of total gemini (16-
NGK-16), that is 1 % of the total lipid content, in formula GNP1 with DOTA-conjugated gemini 
surfactant (16-NG-DOTA-16) during the preparation of the lipid film, and the same procedures 
for the preparation of gemini nanoparticles were followed. Fab-DOTA-NP were prepared by 
replacing 5 % (w/w) of gemini surfactant content in formula GNP1 (1 % w/w of total lipid 
composition) with DOTA-conjugated gemini surfactant (16-NG-DOTA-16) and 5% w/w of 
gemini surfactant in the formulation (1 % w/w of total lipid composition) by Fab-conjugated 
gemini surfactant (16-NG-Fab-16) (Table 1).  To prepare Fab-DOTA-NP, Fab-PEG-gemini 
aqueous solution (0.4 mg/mL) was added dropwise with continuous stirring to 0.5 mL of 
nanoparticle dispersion. After an incubation time of 30 minutes at 37°C, the formula was stored at 
–80 °C. The particle size and zeta potential of targeted (Fab-DOTA-NP) and non-targeted (DOTA-
NP) nanoparticles was determined as earlier described.
Fab-binding study using flow cytometry
GPNMB-Fab and Fab-DOTA-NP were labeled using Alexa Fluor® 647 (ex/em 650/668 nm) 
microscale protein labeling kit (Invitrogen, Eugene, OR, USA) according to the manufacturer’s 
protocol. Melanoma-derived cell lines A375, G-361 and WM-115 (primary melanoma) and SH-4, 
SK-MEL-24 and RPMI-7951 (metastatic melanoma) were washed with PBS, detached using 
TrypLETM (gibco, USA), pelleted and resuspended in PBS at a final concentration of 2×106 cells 
/mL. One hundred microliters of cell suspension was incubated with 4.65 µg of labeled Fab, or the 
equivalent amount of labeled nanoparticles, for one hour at room temperature. After incubation, 
cells were washed with PBS, pelleted and resuspended in 500 µL PBS for FACS. To evaluate the 
non-specific binding, a control sample was prepared by incubating the cells with the same 
concentration of unlabeled GPNMB-Fab for half an hour, before adding the labeled Fab. 
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13
Radiolabeling and characterization of gemini surfactant nanoparticles
DOTA-NP and Fab-DOTA-NP were incubated with 111In-acetate (111InCl3/0.5 M ammonium 
acetate) for 1 hour at 37°C. The radiochemical purity (RCP) of 111In-labeled nanoparticles was 
determined by instant thin layer chromatography (iTLC). Plates were developed in 20 mM sodium 
citrate (pH 5.5). 111In-labeled DOTA-NP and 111In-labeled Fab-DOTA-NP remained at the origin 
(Rf = 0), while free 111In-acetate migrated with the solvent front (Rf = 1). The distribution of 
radioactivity in developed iTLC plates was determined using a automated gamma counter (2480 
Wizard2, PerkinElmer, Waltham MA). For stability evaluation, 111In- DOTA-NP and 111In- Fab-
DOTA-NP were added to 0.5 mL PBS or mouse serum in 1:10 volume ratio and were incubated 
at 37°C for 72 hours. At different time points, samples were taken from the stock solution and 
analyzed. Stability was evaluated using iTLC as described above.
In vitro binding and internalization 
In vitro subcellular fractionation study was performed following the manufacturer’s protocol 
(Nuclei EZ Prep Nuclei Isolation Kit; Sigma-Aldrich, Saint Louis, MO) with slight modification. 
RPMI-7951 cells were seeded in 6-well cluster plate at 4×105 cells per well the day prior to the 
assay and the medium was changed one hour prior to the assay. 111In-labeled targeted (Fab-DOTA-
NP. 5.5 µM GPNMB-Fab) and non-targeted (DOTA-NP) nanoparticles were added to the cells 
(15 µL, 0.25 MBq) and incubated in 5 %v/v CO2 humidified atmosphere at 37 °C for 1, 2, 6 and 
24 h. After incubation, cells were put on ice to stop internalization, washed twice with ice-cold 
PBS, detached with 0.25% w/v trypsin and the radioactivity was measured using a gamma counter. 
Thereafter, the cells were washed with acetate buffer (pH = 2.6) to strip nanoparticles bound to 
cell surface and were washed with PBS again and measured using a gamma counter. Finally, the 
cell suspension was vortexed and incubated in ice for 10 min in the presence of Nuclei EZ Lysis 
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Buffer for the isolation of nuclei from cells. The cells were then centrifuged for 5 min at 4 °C 
where the supernatant collected contains the cytoplasmic fraction. The cells were then resuspended 
again in Nuclei EZ Lysis Buffer, and the above procedure was repeated to collect the remaining 
cytoplasmic fraction. The final pellet containing intact cell nuclei was counted using γ-counter to 
determine the amount of 111In.
Pharmacokinetics of 111In- DOTA-NP and 111In- Fab-DOTA-NP
Normal athymic CD-1 nude mice (n = 4) were injected intravenously via a tail vein with 4 − 5 
MBq 111In- DOTA-NP and 111In- Fab-DOTA-NP. Blood samples were collected from a saphenous 
vein at 5 min, 15 min, 30 min, 2, 4, 6, 24, 48 and 72 h post injection into a capillary tube. The 
volume of the blood was determined by measuring the length of the blood sample in the capillary 
tube using a digital caliper and converted to mL knowing the internal dimeter of the capillary tube. 
Thereafter, the radioactivity in the capillary tube was measured in a γ-counter and expressed as 
percentage of the injected activity per mL (% IA/mL). Pharmacokinetic parameters were 
calculated by fitting the blood radioactivity versus time to a two-compartment model using Prism 
5.0 software (GraphPad). The area under the percentage of the injected activity per mL versus time 
curves (AUC), clearance (CL), volume of distribution (Vss), and half-lives (t1/2α, and t1/2β) were 
calculated.
SPECT/CT imaging and biodistribution in mice
Athymic CD-1 nude mice bearing G361xenografts (n = 4) were injected via a tail vein with 15 
– 17 MBq of 111In-Fab-DOTA-NP or of 111In-DOTA-NP. At 2, 24 and 48 hours after injection, 
SPECT and CT images were acquired using MILabs Vector4CT scanner (MILabs B.V., Utrecht). 
SPECT scans were acquired in a list-mode data format with a high-energy ultra-high resolution 
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(XUHS-M) mouse/rat pinhole collimator. Corresponding CT scans were acquired with a tube 
setting of 50 kV and 480 μA. Images were reconstructed using a pixel-based order-subset 
expectation maximization (POS-EM) algorithm that included resolution recovery and 
compensation for distance-dependent pinhole sensitivity and were registered on CT and quantified 
using PMOD 3.8 software (PMOD, Switzerland). Tracer uptake was expressed as percentage 
injected activity (% IA) per volume (cc) of tissue volume (% IA/cc). All quantification data was 
reported as mean ± standard deviation within one animal study group.
For biodistribution study, the animals were euthanized under deep anesthesia after the last 
imaging point and tissue samples including small intestine, stomach, lung, heart, muscle, liver, 
spleen, kidneys and tumor were harvested. Samples of selected tissues were excised and weighed 
and the amounts of radioactivity in tissue samples were measured using γ-counter. The 
radioactivity in the organs was expressed as percent injected activity per gram (% IA/g). 
All animal experiments comply with the ARRIVE guidelines  23 and were carried out in accordance 
the National Institutes of Health guide for the care and use of Laboratory animals National 
Research Council (US) Committee for the Update of the Guide for the
Care and Use of Laboratory Animals, Guide for the Care and Use of Laboratory Animals, Guide 
for the Care and Use of Laboratory Animals, 2011 <https://doi.org/10.17226/12910>.. The study 
protocol was approved by Animal Research Ethics Board (AREB), University of Saskatchewan 
(protocol number 20150044).
Statistical analyses
All characterization experiments were performed in triplicates at the minimum and the results 
are expressed as mean values ± standard deviation. Statistical analyses was evaluated by one-
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way analysis of variance (ANOVA) followed by the Bonferroni post hoc test using SPSS version 
23.0 (SPSS, IBM Company, Chicago, USA). Significant differences were considered at p <0.05 
values.
Results 
Formulation and characterisation of gemini surfactant nanoparticles
Gemini surfactants nanoparticles were prepared using gemini surfactant (16-NGK-16), DOPE, 
DPPC and DSPC as helper lipids in different molar ratios (Table S.1). The prepared nanoparticles 
had a particle size ranging from 70 - 180 nm. The polydispersity index (PDI) of the nanoparticles 
was approximately 0.2 and the zeta potential ranged from 10 - 17 mV (see supplementary data). 
Formula GNP1 with particle size of 85.42 ± 0.68 nm (PDI 0.18 ± 0.01) and zeta potential of 17.07 
± 1.18 mV was chosen for DOTA and GPNMB Fab conjugation. TEM images (Fig. 1) show round 
particles less than 100 nm in diameter with no aggregations. The particle size of non-targeted 
gemini surfactant nanoparticles (DOTA-NP) and targeted gemini surfactant nanoparticles (Fab-
DOTA-NP) was found to be 105.1 ± 2.98 nm (PDI 0.19 ± 0.0125) and 127.566 ± 2.45 (PDI 0.341 
± 0.0006), respectively. Based on the size of Fab-DOTA-NP and the mean molecular area of 
GPNMB-Fab-conjugated gemini surfactants (a0=7) 22, the number of GPNMB-Fab per one 
nanoparticle was calculated to be approximately 50. 
Flow cytometry of gemini surfactant nanoparticles
The cellular uptake of gemini surfactant nanoparticles formula GNP1 was investigated in two 
melanoma cell lines, RPMI-7951 and A375 using flow cytometry. Two fluorescent dyes; the 
hydrophilic FITC-dextran and the hydrophobic DiO were used to label the nanoparticles. Flow 
cytometry showed that cells treated with dye solutions exhibited small or no shift in their 
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fluorescence compared to a significant shift observed with the fluorescent nanoparticles (Fig. 2), 
which was confirmed by confocal microscopy imaging (Fig. 3).
The binding of GPNMB-Fab conjugated nanoparticles in melanoma cell lines A375, G-361, 
WM-115, SH-4, SK-MEL-24 and RPMI-7951 was studied by flow cytometry (Fig.4). As a control, 
non-labeled antibody was used to block the receptors to study the specificity of binding. In case of 
RPMI-7951 cells, there was a remarkable shift in cell fluorescence in case of GPNMB-Fab-treated 
cells compared pre-blocked cells. In case of SH-4, the GPNMB-Fab treated cells and the pre-
blocked cells were almost superimposed. The fluorescence shift in case of G361, SK-MEL-24 and 
A374 was less than that of RPMI-7951 but greater than for SH-4 cells. In order to investigate the 
effect of GPNMB-Fab conjugation with gemini surfactant nanoparticles on the binding to 
melanoma cells surface GPNMB receptors, the surface binding of Fab-DOTA-NP to two 
melanoma cell lines, namely, RPMI-7951 and A375 was investigated. There was no difference in 
fluorescence intensity between the unconjugated Fab and Fab-conjugated nanoparticles, indicating 
similar extent of binding at that concentration (Fig. 4 1b & 2b). 
111In-labeling and stability of DOTA-NP and Fab-DOTA-NP  
The radiochemical purity in case of 111In-labeled DOTA-NP was 97.6 ± 1.7% and in case of 111In-
labeled Fab-DOTA-NP was 98.2 ± 1.6%, therefore, no further purification was needed. Stability 
of the 111In labeled nanoparticles was studied in PBS and mouse serum using ITLC. No 
transchelation was observed for 111In-DOTA-NP after 72 hours incubation in mouse serum and 
PBS, while 111In-Fab-DOTA-NP showed a noticeable transchelation in mouse serum (3 %) and 
PBS (5.3 %). 111In-DOTA-NP and 111In-Fab-DOTA-NP were considered stable with only a small 
further increase in tranchelation after one week incubation (Fig. S.2).
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Intracellular distribution of 111In-DOTA-NP and 111In-Fab-DOTA-NP  
We compared the in vitro intracellular distribution of non-targeted 111In-DOTA-NP and 
GPNMB targeted 111In-Fab-DOTA-NP (Fig. 5). Cell binding and intracellular uptake of targeted 
111In-Fab-DOTA-NP was significantly (p < 0.05) higher than for non-targeted 111In-DOTA-NP at 
all time points. After one hour incubation 10.09 ± 1.40 % of 111In-Fab-DOTA-NP was bound to 
RPMI cells versus 2.75 ± 0.71 % of 111In-DOTA-NP (p < 0.05). Cell binding of nanoparticles 
peaked at six hours after incubation with 14.40 ± 2.33 % for 111In-Fab-DOTA-NP compared to 
4.42 ± 0.11 % for 111In-DOTA-NP. Nuclear localization of GPNM targeted 111In-Fab-DOTA-NP 
was more than 5-fold higher than (p < 0.05) for non-targeted 111In-DOTA-NP (9.30 ± 2.11 % 
versus 1.85 ± 0.33 %).  
Pharmacokinetics of 111In- DOTA-NP and 111In- Fab-DOTA-NP
The pharmacokinetics of targeted 111In-Fab-DOTA-NP and non-targeted 111In-DOTA-NP was 
studied in healthy athymic CD-1 mice. 111In-Fab-DOTA-NP and 111In-DOTA-NP followed a bi-
phasic elimination. There was a significant difference (p < 0.05) in the pharmacokinetic parameters 
of 111In-Fab-DOTA-NP (AUC = 67.0 ± 13.2 % IA/mL × h, Vss = 60.2 ± 19.6 mL, CL = 1.22 ± 0.21 
mL/h and distribution half-life t1/2α = 0.6 ± 0.5 h) compared with 111In-DOTA-NP (AUC = 127.9 ± 
13.8 % ID/mL × h, Vss = 21.8 ± 1.5 mL and CL = 0.8 ± 0.1 mL/h). There was no significant 
difference (p > 0.05) in the elimination half-life t1/2β of the GPNMB targeted 111In-Fab-DOTA-NP 
(27.4 ± 3.6 h) compared with non-targeted 111In-DOTA-NP (21.6 ± 2.1 h) (Fig. 6 and Table 2). 
SPECT/CT imaging and biodistribution study in melanoma xenograft-bearing mice
Representative slices of microSPECT/CT images of a mouse bearing G361 melanoma 
xenograft injected with 111In-Fab-DOTA-NP or 111In-DOTA-NP at 2, 24 and 48 hours post 
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injection are shown (Fig. 7A & B). It is to be noted that RPMI-7951 cell line, which shows the 
greater binding affinity to GPNMB-Fab, was not used in the imaging studies because it did not 
develop subcutaneous xenograft in mice.
There was lower tumor uptake of the GPNMB targeted 111In-Fab-DOTA-NP compared with 
non-targeted 111In-DOTA-NP at all time points. The high activity uptake by the liver and spleen is 
another important observation for both targeted and non-targeted nanoparticles.  Quantification of 
the decay-corrected images (Fig. 7C) confirmed significantly (p < 0.05) higher tumor uptake of 
non-targeted nanoparticles: 5.23 ± 0.55, 5.77 ± 0.57 and 5.47 ± 0.46 %IA/cc at 2, 24 and 48 hours, 
compared with the targeted nanoparticles; 1.53 ± .01, 2.08 ± 0.36 and 1.87 ± 0.27 %IA/cc at the 
corresponding time points. Ex vivo biodistribution results were similar to the microSPECT imaging 
(Fig. 8). The highest activity accumulation was observed in the liver and spleen for both the 
targeted and non-targeted nanoparticles. For instance, spleen uptake of 111In-Fab-DOTA-NP was 
84.45 ± 26.20 versus 30.72 ± 2.88 %IA/g for 111In-DOTA-NP. On the other hand liver uptake for 
the targeted nanoparticles (10.09 ± 4.84 %IA/g) was significantly lower than that of the non-
targeted nanoparticles (21.32 ± 1.26 %IA/g). Significantly higher uptake (p < 0.05) was seen in 
the lung, heart, skin and brain for the non-targeted 111In-DOTA-NP compared with the GPNMB 
targeted 111In-Fab-DOTA-NP. Ex vivo biodistribution also confirmed higher tumor (p < 0.05) 
uptake of non-targeted 111In-DOTA-NP (4.31 ± 0.40 %IA/g) compared with 111In-Fab-DOTA-NP 
(1.37 ± 0.18 %IA/g) at 48 hours post injection.  
Discussion
Gemini surfactants assemble spontaneously into complex supramolecular structures (micelles, 
bilayers and vesicles) 1000-fold more efficiently compared to their monovalent analogues 25.  The 
Page 19 of 45
ACS Paragon Plus Environment
Molecular Pharmaceutics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
20
low critical micelle concentration (CMC) is beneficial to minimize the amount of gemini surfactant 
needed in the formulation process, which in turn ensures an optimal safety profile and reduces the 
cost of the delivery system 26. Cancerous cells overexpress the negatively charged 
phosphatidylserine on the cell membrane compared to normal tissues. Previous research results 
have found that human melanoma cells express a higher level phosphatidylserine compared to 
other cancer types 27. This adds additional advantage to gemini surfactants nanoparticles, with 
cationic head groups, as a delivery system for cancer cells and specifically melanoma. 
In the present study lipid film hydration method was applied to prepare gemini surfactant-
based nanoparticles by the aid of DOPE, DPPC or DSPC.  The particle size of the nanoparticles 
fell in the range of 50-200 nm, which is optimal for cellular uptake 28. Polydispersity index  of the 
prepared formulae was ≤ 0.2 indicating narrow range of particle size distribution 29 (Table S.1). 
To study the cellular uptake of the gemini surfactant nanoparticles, two fluorescent dyes were 
loaded to the nanoparticles; the hydrophilic FITC-dextran (log p = 2) 30 and the hydrophobic DiO 
(log p = 5) 31, and the cellular uptake was examined using flow cytometry (Fig. 2). It is clear that 
FITC-dextran and DiO are not taken up by the cells unless they are incorporated with the 
nanoparticles. Similar results could be seen in confocal microscopic images (Fig. 3) of cells 
internalising fluorescent nanoparticles while those treated with dye solutions exhibited little or 
almost no fluorescence.  
Active targeting of nanoparticles with monoclonal antibodies can enhance their uptake by 
cancer cells that over express the target antigen 32. Fab fragment-modified nanoparticles exhibit 
longer systemic circulation than those modified with whole immunoglobulin G since 
reticuloendothelial system uptakes nanoparticles via the Fc receptor-mediated mechanism 33,34. 
GPNMB is a glycosylated transmembrane protein that is overexpressed in melanoma among other 
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types of cancer 35. Anti-GPNMB antibody Fab fragment (GPNMB-Fab) was chosen as a targeting 
moiety.  To understand the binding affinity of GPNMB-Fab to melanoma, six melanoma cell lines 
were screened by flow cytometry (Fig. 4). The cell lines were selected to represent different types 
of melanoma tumors and variable degrees of GPNMB antigen expression as reported in the 
literature.  Three primary melanoma cell lines; A375, G-361 and WM-115, and three metastatic 
melanoma cells SH-4, SK-MEL-24 and RPMI-7951have been investigated. RPMI-7951, G361 
and SK-MEL-24 are reported to be highly expressing GPNMB antigen 11, A375 weakly expresses 
the antigen 36, whereas, WM-115 and SH4 had not been tested before. The results showed that the 
degree of cellular binding depends on the level of antigen expression. RPMI-7951 cells showed 
the highest binding affinity among the cell lines tested, SH4 exhibited the lowest binding capacity, 
and the rest of the cell lines showed intermediate affinity compared to these two cell lines. 
To formulate gemini surfactant nanoparticles radiolabeled with 111In and actively targeted with 
GPNMB-Fab, DOTA-conjugated gemini surfactant (16-7NG-DOTA-16) and Fab-conjugated 
gemini surfactant (16-7NG-Fab-16) were synthesized and characterised by mass spectroscopy, 1H 
NMR and RP-HPLC (Fig. S.1). Flow cytometry was used to confirm that conjugation did not 
affect binding to cells. Subcellular fractionation experiment was carried out to investigate the 
intracellular fate of 111In-labeled targeted (111In-Fab-DOTA-NP) and non-targeted (111In-DOTA-
NP) nanoparticles (Fig. 5). Over 24 hours, the surface binding and nuclear uptake of the targeted 
nanoparticle was significantly higher than the non-targeted nanoparticles. This indicates that 
GPNMB-Fab targeted nanoparticles can be more effective than non-targeted nanoparticles at 
releasing cytotoxic payloads to the vicinity of the nucleus of melanoma cancer cells where they 
can cause enhanced DNA damage and hence cell death 37. 
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As observed in the pharmacokinetic parameters, the AUC of the Fab-targeted nanoparticles 
(67.0 ± 13.2% IA hr/mL) is about half that of the non-targeted nanoparticles (127.9 ± 13.8% IA 
hr/mL) which indicates that less of the targeted formulation was circulation for efficient tumor 
uptake. Similarly, the volume of distribution of the targeted nanoparticles (60.2 ± 19.6 mL) was 
almost three times greater than non-targeted nanoparticles (21.8 ± 1.5 mL) which reflects the high 
spleen uptake of the targeted nanoparticles. SPECT/CT imaging showed that tumor uptake in case 
of non-targeted nanoparticles was greater than the targeted nanoparticles (Fig. 7C), with maximum 
uptake at 24 hours. By decay corrected quantification of images, a significant difference in the 
radioactivity was detected between the targeted and non-targeted nanoparticles, with the greatest 
uptake (5.77 ± 0.57 %IA/cc) at 24 hours for the non-targeted nanoparticles. The main mechanism 
of targeting nanoparticulate delivery systems is passive targeting derived by the EPR effect which 
is due to the leaky vasculature and the poor lymphatic drainage of tumors 38. The physicochemical 
properties of the nanoparticles such as the particle size, surface charge in addition to the tumor 
microenvironment, all determine the extent of nanoparticles extravasation to the tumor 39. In our 
study, the non-targeted and targeted nanoparticles have the optimal size for tumor uptake (105.1 ± 
2.0 and 127. 6 ± 2. 5 nm, respectively). Besides, the positive surface charge imparted by gemini 
surfactant is favorable for tumor cells binding and uptake, as shown by flow cytometry and cell 
fractionation studies. Similar tumor uptake (< 7 %IA/cc) was shown for 111In-labeled liposomes 
in ovarian cancer xenografts  40.   
It is difficult to predict the in vivo behavior of targeted nano-delivery systems. Some studies 
have shown that conjugation of a targeting group improves tumor uptake while others have shown 
that it does not improve tumor uptake 41 42. A number of studies have shown that the active 
targeting of nanoparticle to epidermal growth factor receptors such as Her1/EGFR, and Her2 using 
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ligands such as the epidermal growth factor (EGF) peptide and anti-Her2 monoclonal antibody 
fragments (Fab or single chain Fv) did not result in increased tumor uptake 43,44. In this regard, 
Kirpotin et al showed that active targeting of liposome with anti-Her2 monoclonal antibody 
fragment did not lead to an increase in tumor uptake when compared with the non-targeted 
formulation 45. In another study, Fonge et al showed that tumor uptake of the non-targeted block 
copolymer micelles was significantly higher than that of EGF-targeted micelles in a breast cancer 
xenograft model 46. They also found that decreasing the density of the targeting moiety from 5 
mol% to 1 mol% resulted in improved tumor uptake. In the same context, a novel anti-EphA2 
targeted docetaxel antibody directed nanotherapeutic was formulated with 15 scFv / liposome 
compared to 50 GPNMB-Fab fragments per nanoparticles in our study  4748. In addition, the rapid 
blood clearance and high spleen uptake of the GPNMB targeted nanoparticles can be accounted 
for its low tumor uptake. In our case the lower tumor uptake of GPNMB targeted nanoparticles 
can be improved by further optimization of the formulation. 
Conclusion 
111In-labeled gemini surfactant-based nanoparticles were successfully optimized with respect 
to the particle size and surface charge to be optimal for endocytic internalization by tumor cells 
with minimal loss of 111In in mouse serum and PBS upon incubation for one week. In a melanoma 
xenograft model, promising results are shown with the non-targeted formulation compared with 
GPNMB-targeted ones. One approach to improve tumor uptake of GPNMB targeted NP is to 
optimize the density of anti-GPNM Fab on the surface of the nanoparticles, as well as other 
physiochemical characteristics of the nano-delivery system. 
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Figure legends
Scheme 1. Synthesis of (1) 16-7NGK-16; (2) 16-7NG-DOTA-16 and (3)16-7NG-Fab-16. Step 
1a: bis-boc-lysine, HATU, DIPEA, DMF, 18 h. Step 1b: 4 M HCl, dichloromethane, 2 h. (2) p-
SCN-Bn-DOTA, DIPEA, DMSO, 24 h. Step 3a: NHS-PEG1000-COOH, DIPEA, DMSO, 24 h. 
Step 3b: Fab, EDC, NHS, DMF, 3 h.
Fig. 1. Transmission electron microscope (TEM) images of gemini surfactant nanoparticles 
formula GNP1 before and after lyophilisation.
Fig. 2. Cellular uptake of gemini surfactant nanoparticles in (1) RPMI-7951 and (2) A375 
melanoma cells using flow cytometry: a) gemini surfactant nanoparticles loaded with FITC-
dextran and b) gemini surfactant nanoparticles loaded with DiO compared with dye solutions.
Fig. 3. Confocal microscopy images of RPMI-7951 cells (40×) treated with DiO labeled 
nanoparticles (1), DiO solution (2), FITC-dextran nanoparticles (3) and FITC-dextran solution (4); 
bright field (a), green filter (b) and merge(c)
Fig. 4.  Flow cytometry analysis of GPNMB positive and negative cell lines. 1a) binding of 
unconjugated anti-GPNMB Fab to GPNMB positive RPMI-795 cells, 1b) binding of anti-GPNMB 
Fab nanoparticles to RPMI-795 cells; 2a) binding of unconjugated anti-GPNMB Fab to GPNMB 
positive A375 cells, 2b) binding of anti-GPNMB Fab nanoparticles to GPNMB positive A375 
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cells.. Binding of anti-GPNMB Fab to 3) WM115, 4) SK-MEL-24, 5) G361 and 6) SH4 (6) 
melanoma cell lines is shown. NP = nanoparticle
Fig. 5.  In vitro subcellular distribution of non-targeted 111In-DOTA-NP and targeted 111In-Fab-
DOTA-NP in RPMI-7951 melanoma cells. Cancer cells were incubated for 1, 2, 6 and 24 h prior 
to subcellular fractionation. Gamma counting was performed for quantification of 111In-labeled 
nanoparticles in each subcellular fraction (n = 3)
Fig. 6. Pharmacokinetic profile of 111In-Fab-DOTA-NP and 111In-DOTA-NP in athymic CD-1 
nude mice bearing G361 xenografts (Error bars present standard deviation, n = 4).
Fig. 7. Representative microSPECT/CT images of 111In-Fab-DOTA-NP (A) and 111In-DOTA-NP 
(B) in mice bearing G361 melanoma xenograft at 2, 24 and 48 hours post injection. Red cycles 
indicate tumor, C) Tumor accumulation of 111In-Fab-DOTA-NP and 111In-DOTA-NP by 
microSPECT/CT decay corrected image analysis. (Error bars present standard deviation, n = 4, * 
p <0.05)
Fig. 8.  Biodistribution of 111In-Fab-DOTA-NP and 111In-DOTA-NP in athymic CD-1 nude mice 
bearing G361 xenograft at 48 hours after intravenous injection (Error bars present standard 
deviation, n = 4, * p <0.05)
Page 33 of 45
ACS Paragon Plus Environment
Molecular Pharmaceutics
1
2
3
4
5
6
7
8
9
10
11
12
13
14
15
16
17
18
19
20
21
22
23
24
25
26
27
28
29
30
31
32
33
34
35
36
37
38
39
40
41
42
43
44
45
46
47
48
49
50
51
52
53
54
55
56
57
58
59
60
34
Table 1. Composition (presented as % w/w of total lipid) of the DOTA-gemini surfactant nanoparticles 
(DOTA-NP) and GPNMB-Fab-DOTA-gemini surfactant nanoparticles (Fab-DOTA-NP).
Fab-conjugated 
gemini surfactant 
(16-NG-Fab-16)
DOTA-conjugated 
gemini surfactant
 (16-NG-DOTA-
16)
Gemini 
surfactant
(16-7NG-16)
1, 2 dioleyl-sn-glycero-
phosphatidylethanolamine 
(DOPE)
DOTA-gemini 
surfactant 
nanoparticles 
(DOTA-NP)
- 1% 19% 80%
Fab-conjugated 
gemini surfactant 
(16-NG-Fab-16)
1% 1% 18% 80%
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Table 2. Pharmacokinetic parameters of 111In-DOTA-NP and 111In-Fab-DOTA-NP.
† The difference between 111In-Fab-DOTA-NP and 111In-DOTA-NP was significant (p < 0.05)  
 Formulation AUC
†
 (% IA hr/mL ) Vss
† (mL) Cl† (mL/h) t1/2α† (h) t1/2β (h)
111In-Fab-DOTA-NP 67.0 ± 13.2 60.2 ± 19.6 1.5 ± 0.3 0.6 ± 0.5 27.4 ± 3.6
111In-DOTA-NP 127.9 ± 13.8 21.8 ± 1.5 0.8 ± 0.1 1.3 ± 0.4 21.6 ± 2.1
2 hr
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